Prevencio to Present HART PAD Data at ESC Congress

Prevencio will present data on its AI-powered HART PAD blood test for peripheral artery disease at the European Society of Cardiology Congress in Munich on Aug. 31. The company says the test could help detect PAD earlier and support reimbursement momentum after the AMA assigned it a proprietary billing code.

Why it matters: - Peripheral artery disease is common and often underdiagnosed, which can delay treatment and raise the risk of heart attack, stroke, limb amputation and cardiovascular death. - Prevencio’s HART PAD blood test is designed to support earlier detection using a blood-based, AI-driven approach that could be easier to deploy than some current noninvasive options. - The presentation comes as the ESC Congress spotlights artificial intelligence in patient care, putting AI diagnostics in a high-visibility forum.

What happened: - Prevencio announced that data on HART PAD will be presented at the 2026 European Society of Cardiology Congress in Munich, Germany, on Aug. 31, 2026. - HART PAD is an AI-powered, multiprotein blood test for detecting obstructive peripheral artery disease. - The company said the HART platform is built from scalable AI-driven diagnostics and supports tests across multiple cardiovascular conditions.

The details: - James L. Januzzi, chief scientific officer of the Baim Institute for Clinical Research and professor of medicine at Harvard Medical School, said current noninvasive PAD tools have limitations including variable accuracy, limited accessibility, high cost and, in some cases, intravenous contrast and ionizing radiation. - Januzzi said an accurate, AI-powered blood test such as HART PAD has the potential to help clinicians identify disease earlier, improve risk stratification and guide more appropriate diagnostic evaluation and preventive treatment. - Prevencio recently said the American Medical Association issued a proprietary billing code for HART PAD, a step that can help with insurance billing and reimbursement. - Prevencio’s HART platform already has proprietary billing codes supporting its broader portfolio. - The company said HART CADhs has FDA Breakthrough Device Designation. - Prevencio said the company is commercial-stage with Medicare, Medicare Advantage and select commercial reimbursement. - Prevencio said it is expanding commercial adoption through laboratory and health system partnerships. - The company said more than 35 peer-reviewed publications and scientific presentations support the HART platform. - Prevencio said its global intellectual property portfolio protects its AI algorithms and multiprotein diagnostics.

Between the lines: - The ESC Congress “Spotlight on Artificial Intelligence” gives Prevencio a timely stage to position HART PAD as part of a larger shift toward AI-enabled precision diagnostics. - The AMA billing code matters because reimbursement is often a key hurdle between clinical validation and broader adoption. - Prevencio is framing HART as a platform business, not a single-test product, which could increase strategic value if more disease-specific tests gain reimbursement and clinical traction.

What's next: - Prevencio will present the HART PAD data at the ESC Congress on Aug. 31. - The company is signaling continued work to expand reimbursement, clinical evidence and commercial adoption across the HART portfolio. - Prevencio said it plans to build additional reimbursable diagnostic tests across multiple disease areas and therapeutic indications.

The bottom line: - Prevencio is using a major European cardiology meeting to advance both the clinical case and commercial story for its AI-powered blood test platform.